Diabetic Peripheral Neuropathy Management

Immediate Clinical Assessment and Diagnosis

The American Diabetes Association recommends performing a comprehensive neurological examination to confirm diabetic peripheral neuropathy (DPN) and exclude vascular emergencies, including small-fiber function testing and large-fiber function testing 2
Vascular assessment should include palpation of dorsalis pedis and posterior tibial pulses bilaterally, assessment of capillary refill time, and checking for rubor on dependency and pallor on elevation, as up to 24% of diabetic patients aged 55-74 have diminished pedal pulses 1, 3
Ankle-brachial index (ABI) should be obtained to definitively exclude peripheral arterial disease (PAD), as vascular claudication can present similarly but requires different management 1, 3

Peripheral arterial disease should be excluded, as pain with PAD typically occurs predictably with walking and resolves within 10 minutes of rest, whereas neuropathic pain is worse at night and not consistently exercise-related 3, 4
The American College of Cardiology recommends initiating one of the FDA-approved medications, such as pregabalin, duloxetine, or gabapentin, immediately for neuropathic pain relief 2
Duloxetine can be started at 30-60 mg daily, and gabapentin can be titrated gradually to an effective dose, typically 900-3600 mg/day divided 2

Aggressive glucose management is the only intervention that can prevent progression of DPN, with tight glycemic control effectively preventing DPN in type 1 diabetes and improved control modestly slowing progression in type 2 diabetes 2
The American Diabetes Association recommends targeting HbA1c levels according to current diabetes guidelines while avoiding hypoglycemia in elderly patients 1
Comprehensive foot care protocol should include intensified foot surveillance, inspection of feet at every clinical visit, education on daily self-examination, and referral to podiatry for ongoing preventive care 1

Neuropathic pain in diabetes characteristically worsens at night, causing severe sleep disruption, and assessing for depression and anxiety is crucial, as they are present in over two-thirds of patients with moderate-to-severe painful DPN 4
Sleep loss predicts response to analgesics, and relief of pain improves sleep through both direct and indirect pathways, with over 95% of patients with painful DPN having sleep disturbances that require specific attention 4

The treatment plan should be adjusted based on pain relief and side effects, with consideration of switching to alternative first-line agents if inadequate response is observed 2
Annual comprehensive foot examinations are recommended, with more frequent visits given confirmed neuropathy, and chronic painful DPN often requires long-term pharmacotherapy 1, 2